Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers

HIV Medicine

Volumn 10, Issue 3, 2009, Pages 173-181

  Kakuda, Thomas N ^a   Scholler Gyure M ^b   De Smedt, G ^b   Beets, G ^b   Aharchi, F ^b   Peeters, M P ^b   Vandermeulen, K ^b   Woodfall, B J ^b   Hoetelmans, R M W ^b  

^a Tibotec Inc   (United States)

^b TIBOTEC BVBA   (Belgium)

Author keywords

Drug drug interaction; Etravirine; HIV; Tenofovirdisoproxil fumarate

Indexed keywords

ETRAVIRINE; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RESPONSE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MONOTHERAPY; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URIC ACID BLOOD LEVEL; VITAL SIGN; ADOLESCENT; ANALOGS AND DERIVATIVES; BELGIUM; DRUG INTERACTION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BELGIUM; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; ORGANOPHOSPHONATES; PYRIDAZINES; YOUNG ADULT;

EID: 61349103126     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00668.x     Document Type: Article

References (45)

1. De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1- jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): 15 years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005; 48: 1689-1696.
2. Das K, Clark AD Jr., Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-2560.
3. Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-4686.
4. Vingerhoets J, Azijn H, Fransen E et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005; 79: 12773-12782.
5. Gazzard BG, Pozniak AL, Rosenbaum W et al. An open-label assessment of TMC 125 -a new, next-generation NNRTI, for 7 days in HIV-1-infected individuals with NNRTI resistance. AIDS 2003; 17: F49-F54.
6. Gruzdev B, Rakhmanova A, Doubovskaya E et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve, HIV-1-infected subjects. AIDS 2003; 17: 2487-2494.
7. Sankatsing SU, Weverling GJ, Peeters M et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003; 17: 2623-2627.
8. Nadler JP, Berger DS, Blick G et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. AIDS 2007; 21: F1-F10.
9. Cohen CJ, Steinhart CR, Ward D et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. 16th International AIDS Conference. Toronto, ON, Canada, August 2006 [Abstract TuPE0061].
10. Montaner J, Yeni P, Clumeck NN et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a Phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dic 2008; 47: 969-978.
11. Kakuda TN, Schöller-Gyüre M, Workman C et al. Single and multiple dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Ther 2008; 13: 655-661.
12. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
13. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
14. Haubrich R, Cahn P, Grinsztejn B et al. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) vs. placebo in 612 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 790].
15. Johnson M, Campbell T, Clotet B et al. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) vs. placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 791].
16. Kakuda TN, Schöller-Gyüre M, Woodfall BJ et al. TMC125 in combination with other medications: Summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2006 [Abstract PL5.2].
17. Schöller-Gyüre M, Kakuda TN, Van Solingen-Ristea RM et al. No clinically relevant effect of etravirine on digoxin pharmacokinetics in HIV-negative volunteers. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, LA, April 2008 [Abstract P22].
18. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71: 619-627.
19. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De lercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005; 35: 1055-1066.
20. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612.
21. Nelson MR, Katlama C, Montaner JS et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007; 21: 1273-1281.
22. Arribas JR, Pozniak AL, Gallant JE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78.
23. Cassetti I, Madruga JV, Suleiman JM et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-172.
24. Scholler-Gyure M, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and co-administered in HIV-negative volunteers. Antivir Ther 2007; 12: 789-796.
25. Hoetelmans RM, Marien K, De Pauw M et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007; 64: 655-661.
26. Ray AS, Cihlar T, Robinson KL et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304.
27. Kiser JJ, Carten ML, Aquilante CL et al. The effect of lopinavir/ ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83: 265-272.
28. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on co-administration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278-283.
29. Chittick GE, Zong J, Blum MR et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 2006; 50: 1304-1310.
30. Agarwala S, Eley T, Villegas C, Wang Y, Hughes E, Grasela D. Pharmacokinetic interaction between tenofovir and atazanavir co-administered with ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada, April 2005 [Abstract 16].
31. Ford S, Murray S, Anderson M, Ng-Cashin J, Johnson M, Shelton M. Tenofovir renal clearance decreased following co-administration with brecanavir/ritonavir. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, April 2006 [Abstract 38].
32. Tong L, Phan TK, Robinson KL et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51: 3498-3504.
33. Goicoechea M, Liu S, Best B et al. Greater tenofovir-associated renal function decline with protease inhibitor-based vs. nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108.
34. Kiser JJ, Fletcher CV, Flynn PM et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 2008; 52: 631-637.
35. Barditch-Crovo P, Deeks SG, Collier A et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-2739.
36. Dominguez S, Ghosn J, Peytavin G et al. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: The TENOPLUS Study. J Med Virol 2007; 79: 105-110.
37. Gitman MD, Hirschwerk D, Baskin CH, Singhal PC. Tenofovir-induced kidney injury. Expert Opin Drug Saf 2007; 6: 155-164.
38. Kaul S, Bassi K, Damle B et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract A-1616].
39. Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-2096.
40. von Hentig N, Dauer B, Haberl A et al. Tenofovir co-medication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007; 63: 935-940.
41. Gilead Sciences. Viread package insert, 2008.
42. Matal J, Orsag J, Nekvindova J et al. Experimental approaches to studies on drug metabolism and drug interactions in man: Interaction of acyclic nucleoside phosphonates with human liver cytochromes P450 and flavin-containing monooxygenase 3. Neuro Endocrinol Lett 2006; 27 (Suppl. 2): 27-30.
43. Nekvindova J, Masek V, Veinlichova A et al. Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Xenobiotica 2006; 36: 1165-1177.
44. Kakuda TN, Schöller-Gyüre M, Peeters M et al. Pharmacokinetics and pharmacodynamics of TMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 560].
45. Kakuda TN, Wade JR, Snoeck E et al. Pharmacokinetics and pharmacodynamics of the NNRTI TMC125 in treatment experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 762].